{
  "url": "https://openlegislation.uk/veterinary-medicines-regulations-2013/schedule-2/paragraph-22",
  "json_url": "https://openlegislation.uk/veterinary-medicines-regulations-2013/schedule-2/paragraph-22.json",
  "legislation": "uksi/2013/2033",
  "legislation_title": "The Veterinary Medicines Regulations 2013",
  "legislation_url": "https://openlegislation.uk/veterinary-medicines-regulations-2013",
  "path": "schedule/2/paragraph/22",
  "kind": "paragraph",
  "number": "22",
  "heading": "Labelling",
  "text": "(1) The holder of an authorisation under paragraph 14 must ensure that every container used is labelled with—\n(a) a precise description of the product;\n(b) the date on which the product was produced;\n(c) the name and address of the authorisation holder;\n(d) the address of the site named under the authorisation and its authorisation number;\n(e) the instructions for use;\n(f) the expiry date;\n(g) any necessary warnings;\n(h) in the case of an autogenous vaccine or an unauthorised veterinary medicinal product for administration under the cascade, the name of the veterinary surgeon who ordered the product;\n(i) in the case of blood or a stem cell product—\n(i) the identification of the donor animal; and\n(ii) the date of collection.\n(2) In the case of blood or blood constituents there must be no specific therapeutic indication on the label or on any information related to the product.\n(3) In the case of an unauthorised veterinary medicinal product for administration under the cascade the words “this veterinary medicinal product does not hold a marketing authorisation” must appear on the label.",
  "extent": "E+W+S",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Sch. 2 Pt. 2 (paras. 14-25 entitled \"Authorisation of autogenous vaccines, blood-banks, stem cell centres and products manufactured under the cascade\") substituted for Sch. 2 Pt. 2 (paras. 14-19 entitled \"Authorisation of manufacturers of autogenous vaccines\"), Pt. 3 (paras. 20-24 entitled \"Authorisation of blood banks\"), Pt. 4 (paras. 25-29 entitled \"Authorisation of manufacturers of products for administration under the cascade\") and Pt. 5 (paras. 30-35 entitled \"Authorisation of equine stem cell centres\") (E.W.S.) (17.5.2024) by The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), 92"
    },
    {
      "type": "E",
      "label": "E1",
      "text": "This version of this provision extends to England and Wales and Scotland only; a separate version has been created for Northern Ireland only"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2013/2033/schedule/2/paragraph/22",
    "retrieved_at": "2026-10-29T00:44:44.019972+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}